Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

AI drug discovery specialist Recursion Pharmaceuticals is shelving three of its most advanced drug prospects in an effort to cut costs following a merger last year. Alongside its latest quarterly ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025 ...

Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize ...

Clinical trial successes, or even failures, would help it fine-tune its algorithm to allow for better results over time, a classic example of the network effect. Still, until Recursion ...

In server-side JavaScript, you will most likely use the ... writeFileWithPromise(); In this example, we use async/await to take the promise and handle it in a synchronous style.

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not ...

Sept 3 (Reuters) - Nvidia-backed Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to ...

The AI-enabled biotechs Recursion and Exscientia have entered into a merger that will create a company with $850 million in cash and 10 upcoming clinical readouts over the next 18 months, according to ...

Investors signaled approval of Recursion’s supercomputing advance with a buying surge that sent the company’s stock rising 10% Monday, from $8.60 to $9.48. Nvidia was all but flat, rising 0.58 ...